Pulmonary Tuberculosis Clinical Trial
Official title:
Prospective Study of N-acetyltransferase2 (NAT2) Gene and Rifampicin Induced Cytochrome P-450 as Susceptible Risk Factors for Antituberculosis Drug Induced Hepatitis
N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) are two drug metabolizing enzymes. Antituberculosis drug isoniazid is acetylated by NAT2 and forms ultimately a nontoxic compound which is metabolized by CYP2E1 to a toxic metabolite. Slow acetylator genotype of NAT2 and wild type genotype of CYP2E1 gene has been attributed to greater toxicity of ATT drug. Therefore this study has been designed to analyze the genetic polymorphism of NAT2 and CYP2E1 genes in tuberculosis patients who developed drug induced hepatitis upon administration of antituberculosis drug.Polymorphism study of NAT2 and CYP2E1 gene may help in predicting the high risk group of ATT induced hepatitis.
n/a
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02736864 -
Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae
|
N/A | |
Not yet recruiting |
NCT04055441 -
A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut University Hospital
|
||
Completed |
NCT02349841 -
Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis
|
Phase 2 | |
Completed |
NCT01927159 -
Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT01691534 -
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
|
Phase 2 | |
Completed |
NCT00803322 -
Improving Community Based Tuberculosis Care in Ethiopia
|
Phase 4 | |
Withdrawn |
NCT03277742 -
Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz
|
N/A | |
Completed |
NCT00057434 -
Vitamin A Therapy for Tuberculosis
|
Phase 3 | |
Not yet recruiting |
NCT06192160 -
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
|
Phase 2 | |
Recruiting |
NCT06127641 -
Rehabilitation of People With Post-tuberculosis Lung Disease
|
N/A | |
Recruiting |
NCT06058299 -
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
|
Phase 2 | |
Completed |
NCT04550832 -
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
|
Phase 2 | |
Completed |
NCT02912832 -
Prospective Assessment of TBDx Feasibility
|
N/A | |
Completed |
NCT01215851 -
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z)
|
Phase 2 | |
Recruiting |
NCT01503099 -
Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease
|
N/A | |
Completed |
NCT04608955 -
Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081
|
Phase 2 | |
Recruiting |
NCT05046366 -
Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
|
||
Completed |
NCT05896930 -
Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
|
Phase 2 | |
Completed |
NCT02279875 -
A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)
|
Phase 2 | |
Completed |
NCT02554318 -
Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia
|
N/A |